Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
A new anti-inflammatory compound, FR167653, ameliorates crescentic glomerulonephritis in Wistar-Kyoto rats
Autore:
Wada, T; Furuichi, K; Sakai, N; Iwata, Y; Yoshimoto, K; Shimizu, M; Kobayashi, KI; Mukaida, N; Matsushima, K; Yokoyama, H;
Indirizzi:
Kanazawa Univ, Sch Med, Dept Internal Med 1, Kanazawa, Ishikawa 9208641, Japan Kanazawa Univ Kanazawa Ishikawa Japan 9208641 wa, Ishikawa 9208641, Japan Kanazawa Univ, Sch Med, Div Blood Purificat, Kanazawa, Ishikawa 9208641, Japan Kanazawa Univ Kanazawa Ishikawa Japan 9208641 wa, Ishikawa 9208641, Japan Kanazawa Univ, Canc Res Inst, Dept Mol Oncol, Kanazawa, Ishikawa 9208641, Japan Kanazawa Univ Kanazawa Ishikawa Japan 9208641 wa, Ishikawa 9208641, Japan Univ Tokyo, Sch Med, Dept Mol Prevent Med, Tokyo 113, Japan Univ Tokyo Tokyo Japan 113 h Med, Dept Mol Prevent Med, Tokyo 113, Japan
Titolo Testata:
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
fascicolo: 8, volume: 11, anno: 2000,
pagine: 1534 - 1541
SICI:
1046-6673(200008)11:8<1534:ANACFA>2.0.ZU;2-S
Fonte:
ISI
Lingua:
ENG
Soggetto:
INTERLEUKIN-1 RECEPTOR ANTAGONIST; ACTIVATING FACTOR MCAF/MCP-1; TNF-ALPHA; MEMBRANE ANTIBODY; LUPUS NEPHRITIS; URINARY LEVELS; CHEMOKINES; INHIBITOR; EXPRESSION; CYTOKINES;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
29
Recensione:
Indirizzi per estratti:
Indirizzo: Wada, T Kanazawa Univ, Sch Med, Dept Internal Med 1, 13-1 Takara Machi, Kanazawa, Ishikawa 9208641, Japan Kanazawa Univ 13-1 Takara Machi Kanazawa Ishikawa Japan 9208641 an
Citazione:
T. Wada et al., "A new anti-inflammatory compound, FR167653, ameliorates crescentic glomerulonephritis in Wistar-Kyoto rats", J AM S NEPH, 11(8), 2000, pp. 1534-1541

Abstract

The pathophysiologic effects of FR167653 were investigated in a model of crescentic glomerulonephritis induced by a small dose of nephrotoxic serum in Wistar-Kyoto rats. The rats developed crescentic glomerulonephritis by 6 d after the administration of serum. The subcutaneous administration of FR167653 (32 mg/kg) markedly decreased the severity of the renal damage. In a group of rats treated with FR167653 daily from day 0 to day 6, glomerular damage, including crescent formation and proteinuria, was virtually absent. FR167653 markedly decreased urinary levels of monocyte chemoattractant protein-1 (MCP-1). In addition, FR167653 reduced production of MCP-1 protein and transcripts in the diseased kidneys. In a group of rats for which treatment was initiated on day 3, shortly after the appearance of glomerular abnormalities, the progression of renal disease was appreciably retarded, with partial inhibition of MCP-1. In contrast, when rats were treated only on thefirst day, no beneficial effects were observed and severe proliferative and necrotizing glomerulonephritis, with crescent formation, was induced by day 6, with the upregulation of MCP-1. These results suggest that FR167653 may be effective against crescentic glomerulonephritis, possibly via the inhibition of MCP-1. In addition, there was marked reduction in renal injury even when FR167653 treatment was initiated after glomerular inflammation wasestablished, suggesting that the therapeutic application of FR167653 may be clinically useful for human renal diseases.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 31/03/20 alle ore 14:17:47